ProShares Trust - ProShares UltraPro S&P 500 ETF 3x Shares
UPRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.76B
Close$
Share Statistics
| Market cap | $29.76 Billion |
|---|---|
| Enterprise Value | $29.59 Billion |
| Dividend Yield | $1.01 (0.71%) |
| Earnings per Share | $- |
| Beta | 3.11 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2265.7 |
| Enterprise Value to EBIT | -393.61 |
| Enterprise Value to Net Income | -420 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9095▼ 47.08% |
|---|---|
| Total Calls | 2,192,000▲ 10.76% |
| Total Puts | 1,993,600▼ 27.01% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.17%▼ 4.33% |
|---|---|
| Total Invested | $146.02M▼ 60.85% |
| Investors Holding | 125▼ 28.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...